Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Eledon Pharmaceuticals, Inc.
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
July 02, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
June 03, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 28, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 25, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 21, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
November 29, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
November 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
October 23, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
October 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
September 25, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
URGN
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
September 06, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
September 05, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
August 16, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
August 10, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
June 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
May 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 04, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
May 01, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit